ArticleCureus2025
Atypical Femoral Fracture During Long-Term Treatment With Denosumab in Patients With Metastatic Bone Tumors.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The role of the neuro-immune-bone axis in osteoporosis: from bone remodeling imbalance to multi-system interactions.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bone-modifying agents (BMAs) are used to treat metastatic bone tumors and are also administered to reduce bone loss caused by bone metastases. Adverse events, such as osteonecrosis of the jaw and hypocalcemia, have been associated with long-term use of bisphosphonates; however, atypical femoral fracture (AFF) is rare. We encountered a patient who received long-term treatment with denosumab (DEN) and had a history of zoledronic acid hydrate administration. Severe complications may have been prevented if the patient had consulted with an orthopedic surgeon when she developed pain in the left thigh one month before AFF. The provision of relevant information on AFF to patients starting treatment with DEN may lead to its early detection. Since it is important to disseminate rare adverse events to the public, we report the present results based on a literature review.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.